Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
410 articles
A newly identified molecular chain reaction links tau aggregates to neuronal death, revealing ZBP1 as a promising therapeutic target in Alzheimer's disease.
A traditional Chinese herbal formula improves cognition and cerebrovascular health in Alzheimer's mice by activating the LKB1-AMPK-SIRT1 autophagy cascade.
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
Sleep-wake patterns measured by wearables significantly predict dementia risk in 57,000+ older adults, matching the predictive power of genetic testing.
Researchers test a quantile-aggregation approach that may improve how Alzheimer's clinical trials detect treatment effects.
A spatial proteomics platform profiled 700,000+ brain cells, identifying a microglial subset that clusters around amyloid-β plaques in Alzheimer's disease.
A new deep learning model from UCSF predicts Alzheimer's diagnosis and cognitive trajectories from one MRI scan—no expensive multimodal imaging required.
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
27-Hydroxycholesterol triggers microglial senescence through iron dysregulation, and the iron chelator deferoxamine reverses the damage.
Cannabis use is surging among adults over 65, but Stanford Medicine specialists say today's potent marijuana carries serious, underestimated health risks.
Applied Cognition tests a wearable device that tracks glymphatic function overnight, comparing it to MRI, EEG, and blood biomarkers.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
